10,11-Seco-LSD

10,11-Seco-LSD

Clinical data
Other names	"[0124]"; 9,10-Didehydro-N,N-diethyl-6-methyl-10,11-secoergoline-8β-carboxamide
Drug class	Partial ergoline
ATC code	None
Identifiers
CAS Number	2640392-96-5
Chemical and physical data
3D model (JSmol)	Interactive image
SMILES O=C([C@@]1C=C[C@@]([H])(CC2=CN([H])C3=CC=CC=C23)N(C)C1)N(CC)CC
InChI InChI=1S/C20H26N3O/c1-4-23(5-2)20(24)15-10-11-17(22(3)14-15)12-16-13-21-19-9-7-6-8-18(16)19/h6-11,13,17,21H,4-5,12,14H2,1-3H3/t17-/m0/s1 Key:CGFPZODXTFFRAH-KRWDZBQOSA-N

10,11-Seco-LSD is a partial lysergamide and cyclized tryptamine related to lysergic acid diethylamide (LSD).^[1] It is the seco analogue of LSD in which the bond between the 10 and 11 positions of the ergoline ring system has been broken.^[1] 10,11-Seco-LSD was described in a patent by David E. Olson and colleagues at Delix Therapeutics in 2021.^[1] Its pharmacology was not described.^[1]

See also

• Partial lysergamide
• Seco-LSD
• Secoergoline
• NDTDI (8,10-seco-LSD)
• DEIMDHPCA (3,5-seco-LSD)

References

1. WO 2021076572, Olson DE, Dunlap LM, Wagner F, Chytil M, Powell NE, "Ergoline-like compounds for promoting neural plasticity", published 22 April 2021, assigned to Delix Therapeutics, Inc. and The Regents of the University of California